Cadrenal Therapeutics, Inc. (CVKD)
CIK 1937993 · all EDGAR filings →
Same rating bands the category standard uses, but free, with the formula on the chip and the gaps in the data said out loud.
Shares outstanding over time
Latest: 3.6M shares as of Aug 13, 2026 (10-Q).⊙
Cash runway
Going-concern warning
auditor flagged substantial doubt
The company itself flagged going-concern doubt in a filing.
Full breakdown: cash runway tool · source filing →
Warrants
| Tranche | Warrants | Exercise price | Term | Notes |
|---|---|---|---|---|
| Pre Funded Warrant | 960,000 | $0.0001 | — | — |
| Series C1 Warrant | 960,000 | $3.9063 | — | — |
| Common Warrants | 960,000 | not tagged | — | — |
| Pre Funds Warrants | 960,000 | not tagged | — | — |
| Series C One Warrant | 960,000 | $3.1249 | — | — |
| Series C Two Warrant | 960,000 | not tagged | — | — |
| Existing Warrant | 571,430 | $4.5 | — | — |
| Series B1 Warrant | 571,430 | not tagged | — | — |
| New Warrant | 571,430 | $4.5 | — | — |
| June Two Thousand Twenty Six Warrant Issuance | 62,400 | not tagged | — | — |
| April Two Thousand Twenty Six Warrant Inducement | 37,143 | $5.625 | — | — |
| Placement Agent Warrant | 13,479 | $13.5625 | 5y | — |
Tranches exactly as the company dimensioned them in its 10-Q filed Aug 13, 2026 →. Groupings can overlap (a “Series E and F” row is not additive with a “Series E” row), so do not sum this column. A tranche the filer did not tag is absent here, not absent from the cap table. DOWN-ROUND = the filer tagged price-protection accounting scoped to that tranche.
Warrants outstanding: 18,571 underlying shares, as reported Sep 30, 2025 (10-Q).
Reported exercise price: $20.625 (aggregate figure as tagged; individual tranches vary).
Rough fully diluted estimate: 3.6M = 3.6M O/S + 18,571 warrant shares. An estimate, not a filing figure: it ignores converts, options and RSUs, and the two inputs carry different as-of dates.
Convertible notes
No convertible-note facts tagged in the 10-Q filed Aug 13, 2026. If convertible notes exist, their terms live in exhibit prose for this filer and are not parsed; absence of a tag is not proof of absence. The exhibits are the ground truth.
Fully diluted build-up
Shares outstanding plus every potential-share instrument the filer tagged in XBRL, each at its own as-of date. An estimate assembled from filed figures, not a filing figure itself.
| Shares outstanding | 3.6M | Aug 13, 2026 |
| + Pre Funded Warrant (if exercised) | 960,000 | Jun 30, 2026 |
| + Series C1 Warrant (if exercised) | 960,000 | Jun 30, 2026 |
| + Common Warrants (if exercised) | 960,000 | Jun 30, 2026 |
| + Pre Funds Warrants (if exercised) | 960,000 | Jul 1, 2026 |
| + Series C One Warrant (if exercised) | 960,000 | Jul 1, 2026 |
| + Series C Two Warrant (if exercised) | 960,000 | Jul 1, 2026 |
| + Existing Warrant (if exercised) | 571,430 | Jun 30, 2026 |
| + Series B1 Warrant (if exercised) | 571,430 | Jun 30, 2026 |
| + New Warrant (if exercised) | 571,430 | Jun 30, 2026 |
| + June Two Thousand Twenty Six Warrant Issuance (if exercised) | 62,400 | Jun 30, 2026 |
| + April Two Thousand Twenty Six Warrant Inducement (if exercised) | 37,143 | Jun 30, 2026 |
| + Placement Agent Warrant (if exercised) | 13,479 | Jun 30, 2026 |
| Fully diluted estimate | 11.2M | +212.7% vs O/S |
Still excluded, because the filer does not tag them in countable form: employee options and RSUs, any instrument living only in exhibit prose, and instruments above missing a share count. Inputs carry different as-of dates, shown per row. Each figure traces to the tranche and note tables above and their cited filings.
Registrations and offerings
Registered offering capacity on live registrations: $17.8Mfrom the structured fee exhibits; registered is not remaining, takedowns are not subtracted
Last 12 months: 8 executed · 3 registered.
Full history and shelf status: offering checker · S-3 shelf checker
Source: SEC EDGAR XBRL company facts and filing metadata, fetched live and cached briefly. Share counts are cover-page figures with their form named. Warrant tranches and convertible notes come from the dimensioned facts in the latest 10-Q/10-K instance document, exactly as the company tagged them; untagged tranches and notes are absent, not disproven. Nothing on this page is manually verified and nothing is behind a login: what free data supports is shown, what it cannot support is stated. Not investment advice.
Keep going: float checker · offering calendar · short-squeeze screener · full CVKD workspace
Free to use. No account, no card.